ArticleThe American journal of pathology2001
The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease.
Article in The American journal of pathology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 135 citations in OpenAlex.
- Enhancer-driven gene regulatory networks inference from single-cell RNA-seq and ATAC-seq data.Briefings in bioinformatics · 2024Article
- Article
- Usefulness of BATF3 Immunohistochemistry in Diagnosing Classical Hodgkin Lymphoma.Diagnostics (Basel, Switzerland) · 2021Article
- Hodgkin lymphoma.Nature reviews. Disease primers · 2020Review
- The Histone Demethylase LSD1 Regulates B Cell Proliferation and Plasmablast Differentiation.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- The c-Jun and JunB transcription factors facilitate the transit of classical Hodgkin lymphoma tumour cells through GScientific reports · 2018Article
- A Case of Chemotherapy-Refractory "THRLBCL like Transformation of NLPHL" Successfully Treated with Lenalidomide.Case reports in oncological medicine · 2018Article
- Quantifying deleterious effects of regulatory variants.Nucleic acids research · 2017Article
- Epstein-Barr virus and the origin of Hodgkin lymphoma.Chinese journal of cancer · 2014Review
- Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2014Review
- Article
- Hodgkin lymphoma.The Journal of clinical investigation · 2012Review
- Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma.Case reports in oncology · 2012Article
- T cell/histiocyte-rich large B-cell lymphoma: an update on its biology and classification.Virchows Archiv : an international journal of pathology · 2011Review
- T-cell/histiocyte-rich large B-cell lymphoma.Haematologica · 2010Article
- EBV in Hodgkin Lymphoma.Mediterranean journal of hematology and infectious diseases · 2009Article
- Is Hodgkin lymphoma just another B-cell lymphoma?Current hematologic malignancy reports · 2009Review
- Hodgkin lymphoma: an update on its biology with new insights into classification.Clinical lymphoma & myeloma · 2009Review
- The biology of Hodgkin's lymphoma.Nature reviews. Cancer · 2009Review
- Nodular lymphocyte-predominant hodgkin lymphoma or T-cell/histiocyte rich large B-cell lymphoma: the problem in "grey zone" lymphomas.International journal of clinical and experimental pathology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hodgkin's disease (HD) is a lymphoproliferative disease of predominantly B-cell origin. However, the reasons for the incomplete development of the B-cell phenotype and lack of immunoglobulin expression in classical HD (cHD) have not been fully explained. We examined the expression of PU.1 in HD, an Ets-family transcription factor, which regulates the expression of immunoglobulin and other genes that are important for B-cell development. Immunohistochemistry for PU.1 was performed on 35 cases of cHD and 15 cases of lymphocyte predominance HD as well as 67 non-Hodgkin's lymphomas (NHL). Expression of PU.1 was studied by Western blotting in four cHD-derived cell lines and in five NHL cell lines. We also studied the expression of two additional B-cell transcription factors, B-cell-specific activator protein and Oct-2. Our results show a striking lack of PU.1 expression by neoplastic cells in cHD but not in lymphocyte predominance HD. Our study also confirmed that B-cell-specific activator protein but not Oct-2 is not expressed by cHD. Western blotting showed no PU.1 protein expression in the cHD-derived cell lines, with the exception of one cell line of putative monocyte/histiocyte origin. The lack of PU.1 protein expression in cHD likely contributes to the lack of immunoglobulin expression and incomplete B-cell phenotype characteristic of the Reed-Sternberg cells in cHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.